Meccellis Biotech Group SAS reported closing an $8.25 million series B funding round to launch its biological implant technology on the US market. The exercise was supported by investment worth $5 million from Ocean Participations SAS alongside new funds from Volney Development SAS, Nouvelle-Aquitaine Co-Investissement SAS and the Poitou-Charentes business angel network Synergence Invest SAS.

Vitadx SA is preparing to close a new $8.3 million funding round, to ramp European distribution of its automated software platform for early detection of bladder cancer. The system is based on morphology analysis of cells in a urine sample on a digital cytology slide. “Our Visiocyt technology allows urologists to adjust patient pathways and thereby limit the number of invasive procedures necessary to confirm their diagnosis with people already presenting symptoms,” Allan Rodriguez, CEO and co-founder of Vitadx, told BioWorld.

Haystack Oncology Inc. has launched with a $56 million series A round to commercialize technology using circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery for early-stage cancers.

Osler Diagnostics Ltd. has raised $85 million in a series C round, as it embarks on clinical testing to secure regulatory approvals for its portable central lab quality diagnostics system.

Shanghai Easy-Flow Medical Technology Co. Ltd. has completed an angel round to develop its peripheral intervention products. The round, which the company claims to be in the “tens of millions of yuan,” was led by Legend Capital.

Predictive analytics startup Intus Care Inc. scooped up $14.1 million in a series A round led by Deerfield Management. The funds will be used to advance and scale its software platform for geriatric care.

Cresilon Inc. raised $25 million in a series A-4 financing round led by Paulson Investment Co. The funds will be used to commercialize its plant-based hemostatic gel for human applications and bring it to global veterinary markets. Known as Vetigel in animal medicine, the product is used by veterinarians to instantly stop bleeding in dental and surgical procedures and emergency situations in the U.S., U.K., Europe and Canada.

Axoft Inc. emerged from stealth mode with an $8 million seed round led by The Engine, the Massachusetts Institute of Technology’s venture spinout for early-stage tech startups. The funds will be used to conduct preclinical studies and scale up prototypes of its supple brain implant technology.